Advocacy intelligence hub — real-time data for patient organizations
IRCCS Azienda Ospedaliero-Universitaria di Bologna — NA
Jonsson Comprehensive Cancer Center
Alunbrig: FDA approved
Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Alunbrig
(brigatinib)Orphan drugTakeda Development Center Americas, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multip...
Giuseppe Lombardi, MD
Istituto Oncologico Veneto IOV IRCCS
Amar Kishan, M.D
UCLA / Jonsson Comprehensive Cancer Center
📍 LOS ANGELES, CA
Ricci Claudio, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Patrick VQ Nguyen
Centre de Recerche du CHUM
Bret Goodpaster, PhD
Translational Research Institute for Metabolism and Diabetes
Lindsay Farrer, PhD
Chief, Genetics Program, Boston University
📍 BOSTON, MA